Skip to content

Study · Animal study (in vivo) · mouse · 2022

4 results

SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism.

Ivashko-Pachima Y, Ganaiem M, Ben-Horin-Hazak I, Lobyntseva A, Bellaiche N, Fischer I, Levy G, Sragovich S, Karmon G, Giladi E, Shazman S, Barak B, Gozes I

Molecular psychiatry10 May 2022Cited by 46 (Europe PMC)

PMID35538192 (opens in a new tab)DOI10.1038/s41380-022-01603-w (opens in a new tab)PepBankPUB-35538192
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice homozygous for Shank3 InsG3680, NAP treatment ameliorated aberrant behavior.

    In plain wordsIn mice with a Shank3 mutation, NAP treatment improved abnormal behavior.

    Peptide
    Davunetide
    Outcome
    Direction not reportedAberrant behavior
    Study

    mousen: not reported in source

    Homozygous Shank3 InsG3680 mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, NAP treatment ameliorated aberrant behavior in mice homozygous for the Shank3 ASD-linked InsG3680 mutation, revealing a fundamental shared mechanism between ADNP and SHANK3.
  2. 02LabEx vivo tissueMechanism

    In mouse brain extracts, NAP normalized Shank3–Adnp–actin interactions.

    In plain wordsIn lab tests with mouse brain extracts, NAP normalized Shank3–Adnp–actin interactions.

    Peptide
    Davunetide
    Outcome
    Direction not reportedShank3–Adnp–actin interactions
    Study

    mousen: not reported in source

    Mouse brain extracts
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Actin co-immunoprecipitations from mouse brain extracts showed NAP-mediated normalization of Shank3-Adnp-actin interactions.
  3. 03LabIn vitro (cells)Mechanism

    In cells with ADNP mutations, NAP normalized microtubule activities across all tested mutations.

    In plain wordsIn cells with ADNP mutations, NAP normalized microtubule activities.

    Peptide
    Davunetide
    Outcome
    Direction not reportedMicrotubule activity
    Study

    n: not reported in source

    Cells with ADNP mutations
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP normalized MT activities in the face of all ADNP mutations, although, SKIP, missing the SH3-binding motif, showed reduced efficacy in terms of MT-Tau interactions, as compared with NAP.
    1 context sentence
    Summary · context
    Comparisons of the effects of ADNP mutations p.Glu830synfs*83, p.Lys408Valfs*31, p.Ser404* on MT dynamics and Tau interactions (live-cell fluorescence-microscopy) suggested spared toxic function in p.Lys408Valfs*31, with a regained SH3-binding motif due to the frameshift insertion.
  4. 04LabIn vitro (cells)Mechanism

    In cells with ADNP mutations, NAP showed greater efficacy for microtubule–Tau interactions than SKIP.

    In plain wordsIn cells with ADNP mutations, NAP supported microtubule–Tau interactions more effectively than SKIP.

    Peptide
    Davunetide
    Outcome
    IncreaseMicrotubule–Tau interactions versus SKIP
    Study

    n: not reported in source

    Cells with ADNP mutations
    Comparator
    SKIP
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP normalized MT activities in the face of all ADNP mutations, although, SKIP, missing the SH3-binding motif, showed reduced efficacy in terms of MT-Tau interactions, as compared with NAP.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.